2012 Program Committee
2012 PROGRAM COMMITTEE CHAIRS AND VICE CHAIRS
H. Kim Lyerly, M.D.,
Dr. Lyerly is the George Barth Geller Professor of Cancer Research and Professor of Surgery at the Duke University Medical Center. He has been named by his peers as one of North Carolina's most outstanding clinical physicians. In addition, he is an internationally recognized expert in cancer therapy and cancer immunotherapy and has published nearly 200 scientific articles and has edited 10 textbooks on surgery, cancer immunotherapy, and novel cancer therapies. He serves on the editorial board of 12 scientific journals. In 2008, Dr. Lyerly was appointed to the National Cancer Advisory Board (NCAB) by President George Bush and was named chair on the Cancer Centers sub-committee of the NCAB. Dr. Lyerly is a highly sought advisor and currently serves on the external advisory boards of the M.D. Anderson Cancer Center, the University of Michigan Cancer Center, the University of Chicago Cancer Center, the University of Alabama Cancer Center, the Boston University Cancer Center, and the Purdue Cancer Center. He also serves as an advisor to the University of Washington, and Case Western Reserve Clinical and Translational Science Institutes. He is currently a member of the Scientific Advisory Board of Susan G. Komen for the Cure. He has previously served as chairperson of the executive committee of the integration panel of the Congressionally Directed Medical Research Programs in Breast Cancer. He also served on American Society of Clinical Oncology's Grants Selection Committee, of which he served as chair in 2006. Dr. Lyerly is a member of the American College of Surgeons, of which he is a fellow. He was invited by former North Carolina Governor Michael Easley to serve on the Advisory Commission of the NC State Museum of Natural Sciences. In 2010, Dr. Lyerly was reappointed as a member of the NC Advisory Committee on Cancer Coordination and Control by Governor Bev Perdue.
Richard Pazdur, M.D.
Dr. Pazdur is presently the Director of the Office of Hematology and Oncology Products in the Center for Drug Evaluation and Research of the U.S. Food and Drug Administration. This Office was formed in 2005 to consolidate the review of drugs and therapeutic biologics for the diagnosis, treatment, and prevention of cancer as well as the review of drugs and therapeutic biologics for hematologic diseases and for medical imaging. Dr. Pazdur's position facilitates coordination of oncology activities across all FDA Centers and ensures an ongoing outreach and collaboration between FDA, the National Cancer Institute, and other cancer-related organizations within and outside of the government. Dr. Pazdur was the Director of the Division of Oncology Drug Products from September 1999 to May 2005. Prior to joining the FDA, Dr. Pazdur was Professor of Medicine at The University of Texas M.D. Anderson Cancer Center in Houston, Texas. Dr. Pazdur was on the faculty of the M. D. Anderson Cancer Center from 1988 to 1999. During his tenure at the M. D. Anderson Cancer Center, Dr. Pazdur held administrative positions of Assistant Vice President for Academic Affairs, Associate Director of Clinical Trials Administration (Division of Medicine) and Director of Educational Programs (Division of Medicine). Dr. Pazdur's main research interests are in clinical trial design and drug development of anti-cancer agents in advanced colorectal cancer. He has performed numerous phase I, II, III, and adjuvant therapy trials in this disease. Dr. Pazdur has published over 300 articles, book chapters and abstracts. Dr. Pazdur was on the faculty of Wayne State University, Detroit, Michigan from 1982 to 1988. He received his undergraduate degree from Northwestern University (Evanston, Illinois), his M. D. degree from Loyola Stritch School of Medicine (Maywood, Illinois), and completed clinical training at Rush-Presbyterian St. Luke's Medical Center (Chicago, Illinois) and the University of Chicago Hospitals and Clinics.
Jeffrey Abrams, M.D.
Dr. Abrams was selected to lead the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) as associate director in June 2007. Dr. Abrams has been a member of CTEP since 1993, when he joined as a clinical research scientist to oversee the breast cancer treatment trials portfolio and participate in clinical trials at the Clinical Center and the National Naval Medical Center.In 2004, Dr. Abrams was appointed chief of the Clinical Investigations Branch and in this position is responsible for the direction of the NCI Clinical Trials Cooperative Group program. This program performs nearly all the phase III cancer treatment trials sponsored by NCI and is the Institute's primary vehicle for conducting definitive, practice-changing clinical trials. As branch chief, Dr. Abrams supervises a staff that collectively oversees, reviews, and coordinates more than 150 active phase III trials in all varieties of cancer. He pioneered the Cancer Trials Support Unit, which has established a national network of physicians to participate in NCI-sponsored Phase III treatment trials.Dr. Abrams, whose NCI achievements have been recognized by five National Institutes of Health Merit Awards and several Performance Awards, is the author of over 70 original publications in the field of breast cancer and clinical trials, eight book chapters, and nine monographs. He is often called upon to speak at national and international meetings on breast cancer diagnosis and treatment as well as methods to enhance the performance of large clinical trials.Dr. Abrams graduated from the medical school of Catholic University of Louvain, Belgium, in 1979. In 1982, he completed an internal medicine residency at St. Agnes Hospital in Baltimore, MD, and an oncology fellowship at the University of Maryland in 1984. A Fulbright scholarship took him to the Jules Bordet Institute in Belgium for a clinical research fellowship in oncology from 1984 to 1985. From 1985 to 1992, Dr. Abrams returned to the University of Maryland where he directed the Breast Cancer Evaluation Program and was Associate Professor of Medicine and Oncology.
Gregory Curt, M.D.
Dr. Curt received his M.D. degree with distinction in research from the University of Rochester School of Medicine in 1977. He subsequently completed his training in internal medicine as an intern and resident at the New England Deaconess Hospital and as a Research Fellow at the Peter Bent Brigham Hospital, Harvard Medical School. Dr. Curt's training in Medical Oncology was completed in the National Cancer Institute's (NCI) Medicine Branch from 1980-1983, following which he coordinated the intramural NCI Phase I Cancer Drug Development Program. At this time, he performed the original testing of novel agents directed at high grade glioma as well as Phase I clinical trials. His basic research explored the molecular mechanisms of drug resistance in cancer cells. Dr. Curt served as deputy director of NCI's Division of Cancer Treatment from 1985-1988, overseeing the Division's extramural research grant and contract portfolios. He was appointed Clinical Director of the National Cancer Institute in 1989. During his years as clinical director, Dr. Curt led the intramural program at NCI increasingly towards translational research involving new therapeutic modalities including anti-cancer drugs, immunotoxins, and vaccines. He was awarded the Outstanding Service Medal of the U.S. Public Health Service in 1992. Dr. Curt joined AstraZeneca Oncology in 2002 as Senior Director and Alliance Manager for the National Institutes of Health. Under his leadership, AstraZeneca has forged important new partnerships with NIH in cancer drug development and cancer prevention and treatment. He is now US Medical Science Lead for Emerging Products, AstraZeneca Oncology and in the lead clinical for US Strategic Alliances. Dr. Curt is chairman of the Life Sciences Consortium Task Force of the CEO Roundtable.
Thomas Fleming, Ph.D.
Dr. Fleming is Professor and Chairman in the Department of Biostatistics and Professor of the Department of Statistics at the University of Washington School of Public Health and Community Medicine. He is also a full member in the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center. In 1987 he was elected a fellow of the American Statistical Association and in 1988 he was the recipient of the Spiegelman Award from the American Public Health Association in recognition of outstanding contributions to public health research, especially in the areas of oncology and HIV infection. In 2002, he was the recipient of the FDA Commissioner's Special Citation Award for extraordinary contributions to the Agency. Dr. Fleming has been involved in AIDS research efforts for nearly 20 years as an advisor to the National Institute of Allergy and Infectious Diseases (NIAID), as a collaborator in NIAID's multi-center multi-institution AIDS cooperative groups, as a consultant to industry, as an advisor to the FDA, as an educator, and as a researcher of new statistical methodology. Dr. Fleming was involved in the development and coordination of NIAID's national clinical trials program for the prevention and treatment of HIV infection and AIDS. Dr. Fleming also served as an advisor to the FDA for 18 years and has been a voting member of numerous advisory committees for the Center for Drug Evaluation Research and the Center for Biologics Evaluation Research. Since 1987, Dr. Fleming has been a member of the DAIDS Data Monitoring Committee that oversees trials conducted by ACTG and CPCRA, and has served as the chair or a member of data monitoring committees for over 100 industry- and government-sponsored clinical trials. Dr. Fleming also served as the Co-PI of the HIVNET Statistical Center and chair of the HIVNET and HPTN Study Monitoring Committees. In the HPTN, Dr. Fleming served as statistician to the perinatal working group, and as lead statistician on five perinatal studies, three of which are completed, including the pivotal HIVNET 012 trial.
Gregory Reaman, M.D.
Dr. Reaman is the Associate Director for Oncology Science in the Office of Hematology and Oncology Products in the Center for Drug Evaluation and Research of the United States Food and Drug Administration. He is the Founding and Immediate Past Chair of the Children's Oncology Group (COG). The COG is comprised of over 200 member institutions, dedicated to clinical, translational, and epidemiology research in childhood cancer.Dr. Reaman is a Professor of Pediatrics at The George Washington University School of Medicine and Health Sciences and a member of the Division of Hematology-Oncology at the Children's National Medical Center in Washington, D.C., which he directed for more than 17 years and Executive Director Emeritus of the Center for Cancer and Blood Disorders. Dr. Reaman serves or has served on the Editorial Boards of Leukemia, Journal of Clinical Oncology, Journal of Pediatric Hematology/Oncology, Pediatric Blood and Cancer, The Oncologist, Cancer, and Physicians Data Query (PDQ), National Cancer Institute as well as www.PLWC.org (People Living with Cancer). He has served as an Associate Editor of Cancer and Leukemia and Lymphoma. He held the position of Executive Director for Scientific and Medical Affairs for the National Childhood Cancer Foundation and was a member of its Board of Trustees. Previously, he served on the Board of Directors of the American Cancer Society and chaired its Task Force on Children and Cancer. Dr. Reaman served on the Board of Directors of the American Society of Clinical Oncology and has served on the ASCO Patient Education Committee, the Education and Program Committees, the Grant Selection Committee, and was the Chair of the ASCO Membership Committee. Also, he was a member of the Food and Drug Administration's Oncologic Drugs Advisory Committee and has chaired its Pediatric Subcommittee. He was a member of the NIH Roadmap Working Group. He serves on the Scientific Steering Committee of the United Kingdom Children's Cancer and Leukaemia Group, the External Advisory Board of the Cancer Treatment and Research Center at the University of Texas Health Science Center at San Antonio and is a Senior Advisor to the Middle East Childhood Cancer Alliance.Additionally, he is a member of the Data Safety Monitoring Board of the National Cancer Institute's Clinical Oncology Program, and a member of the NCI's Translational Research Working Group. His research interests are in the biology and treatment of childhood acute leukemia and new drug development for pediatric cancers.He is the author of more than 300 peer- reviewed manuscripts and 16 book chapters.
Ms. Thompson was named president of Susan G. Komen for the Cure® in September 2010 after serving as Komen for the Cure's senior vice president of medical and scientific affairs. She is a highly respected leader in the global cancer community, recognized for her passion for driving innovation in science and medicine, and her expertise in formulating educational and public policy initiatives focused on quality and outcomes. As president, she is responsible for a global research portfolio that totals $685 million over Komen's 29 years, and a community health outreach program that has invested more than $1.3 billion into thousands of programs that provide screenings, education, support and outreach programs throughout the U.S. and globally through partnerships in more than 50 countries.A well-known expert in the cancer health arena, Thompson joined Komen in 2008 as managing director, public and medical affairs. She has overseen the organization's strategic relationships with large associations, community education and outreach programs, and global outreach strategies. She has excelled in initiating, developing and managing innovative programs in breast cancer research while maximizing the promise of Komen for the Cure.Her oversight of Komen's education portfolio has involved direct patient education and specific initiatives that impact patient care, access and outcomes, such as clinical trials, regulatory controls, FDA issue management and interfacing with the National Cancer Institute. Ms. Thompson has a Bachelor of Science degree from the University of South Dakota where she was in the Tom Brokaw School of Communications. She reports to Komen founder and CEO Nancy G. Brinker.
Margaret Foti, Ph.D., M.D. (h.c.)
Dr. Foti is the chief executive officer of the American Association for Cancer Research (AACR). The AACR is the oldest and most prestigious cancer research organization in the world. Under her visionary leadership, it has grown to more than 34,000 scientists and physicians working in more than 90 countries, and is renowned as the world's leading organization dedicated to the prevention and cure of cancer. A graduate of Temple University, Dr. Foti has been one of the most influential voices in advancing the field of cancer research, both in the United States and abroad. She was elected president of three professional societies in scholarly publishing and in cancer research. She has also served as a board member, committee member and consultant to a number of other non-profit organizations. There is a legacy of young women and minority scientists whose careers have been advanced as a result of her mentorship and support. Dr. Foti's contributions have been widely recognized by numerous awards from organizations around the world. Her lengthy list of formal recognitions includes honorary degrees in medicine and surgery from three universities in Italy and Spain. Under Dr. Foti's leadership, the AACR has served with distinction as a scientific partner of Stand Up To Cancer. In this capacity, Dr. Foti and the AACR have brought extraordinary expertise and energy to their work with Stand Up To Cancer, especially in the scientific peer review of projects, scientific project management and administration.
Allen Lichter, M.D.
Dr. Lichter is Chief Executive Officer of the American Society of Clinical Oncology (ASCO). Dr. Lichter became Chief Executive Officer of ASCO in October 2006. For the past two decades, Dr. Lichter served at the University of Michigan, first as Chair and Professor of Radiation Oncology, and subsequently as Dean of the Medical School (1998-2006). Dr. Lichter was named the first Isadore Lampe Professor of Radiation Oncology, an endowed chair at the University. Dr. Lichter was also honored as a Newman Family Professor of Radiation Oncology in 2000. Prior to his tenure at the University of Michigan, Dr. Lichter was the Director of the Radiation Therapy Section of the National Cancer Institute's (NCI's) Radiation Oncology Branch. A Member of ASCO since 1980, Dr. Lichter has assumed many prominent roles in the Society, including President (1998-1999) and Founding Chair of The ASCO Foundation Board. He has served on ASCO's Board of Directors and as Chair of the Public Issues Committee, Special Awards Selection Committee, and Co-chair of the Fellows Task Force. Dr. Lichter has served multiple terms on ASCO's Scientific Program Committee as well as on the Nominating, Audit, and Finance Committees, and as an Associate Editor of ASCO's Journal of Clinical Oncology. Dr. Lichter has also held board positions with the Liaison Committee on Medical Education, the Accreditation Council for Graduate Medical Education, the American Society for Therapeutic Radiology and Oncology, and the NCI. Dr. Lichter was a co-editor of the textbook Clinical Oncology and several books on breast cancer, and the author of over one-hundred scientific papers. He has served on the editorial boards of Oncology, the Journal of the National Cancer Institute, and the International Journal of Radiation Oncology, Biology, and Physics. Dr. Lichter earned a bachelor's degree (1968) and medical degree (1972) from the University of Michigan. He trained in radiation oncology at the University of California, San Francisco, before joining the faculty at Johns Hopkins University, and later the NCI.
PROGRAM COMMITTEE MEMBERS
C. Glenn Begley, M.D., Ph.D.
Dr. Begley is an independent consultant to the biotechnology and pharmaceutical industry. He currently serves on the Board of Directors and as Senior Clinical Advisor to Oxford BioTherapeutics, a privately held biotechnology company in Oxford, UK. From 2002-2013 he was employed at Amgen, where he was Vice President and Global Head of Hematology and Oncology Research. In that role he was responsible for building Amgen's Hematology and Oncology research program, and for strategy, direction, coordination and integration of the research effort at Amgen sites in Thousand Oaks, San Francisco, Seattle, Burnaby and Cambridge, MA. During that time over 20 clinical-stage molecules emerged from his group.
Carolyn Compton, M.D., Ph.D.
Dr. Compton is President of the Critical Path Institute, and formerly the Director of the Office of Biorepositories and Biospecimen Research (OBBR) and the Executive Director of the Cancer Human Biobank (caHUB) project at the NCI. She received her MD and PhD degrees from Harvard Medical School and the Harvard Graduate School of Arts and Sciences. She trained in Pathology at Harvard’s Brigham and Women’s Hospital and is boarded in both Anatomic Pathology and Clinical Pathology. She came to the NCI from McGill University where she had been the Strathcona Professor and Chair of Pathology and the Pathologist-in-Chief of McGill University Health Center from 2000-2005. Prior to this, she had been a Professor of Pathology at Harvard Medical School, the Director of Gastrointestinal Pathology at the Massachusetts General Hospital, and the Pathologist-in-Chief of the Shriners’ Hospital For Crippled Children, Boston Burns Unit for 15 years. During this time she served as the Chair of the Pathology Committee of the Cancer and Leukemia Group B for 12 years. Her research interests are in colon and pancreatic cancer as well as epithelial biology and wound healing. Dr. Compton has held many national and international leadership positions in pathology and cancer-related professional organizations. She is a Fellow of the College of American Pathologists (CAP) and a Fellow of the Royal Society of Medicine. Currently, she is the Chair of the American Joint Committee on Cancer (AJCC), serves on the Executive Committee of the Commission on Cancer of the American College of Surgeons, and serves as the Pathology Section Editor for Cancer. She is a past Chair of the Cancer Committee of the College of American Pathologists and was Editor of the first edition of the CAP Cancer Protocols (Reporting on Cancer Specimens) used as standards for COC accreditation. Among her awards are the ISBER Award for Outstanding Achievement in Biobanking, the NIH Director's Award, the NIH Award of Merit, and the CAP Frank W. Hartman Award. She has published more than 500 original scientific papers, reports, review articles, books and abstracts.
Joseph Gootenberg, M.D.
Dr. Gootenberg is Deputy Division Director of the Division of Biologic Oncology Products 2, Office of Oncology Drug Products, Centerfor Drug Evaluation and Research at the U.S. Food and Drug Administration (FDA). Prior to joining the FDA Dr. Gootenberg was Director of Pediatric Hematology/Oncology at the Vincent T. Lombardi Cancer Center and Department of Pediatrics, Georgetown University School of Medicine. Dr. Gootenberg graduated from Harvard College and received his M.D. degree from the Albert Einstein College of Medicine. He served his Pediatric Residency at Boston Children’s Hospital, and completed his Fellowship in Pediatric Hematology/Oncology at the National Cancer Institute where he pursued postdoctoral training in cellular immunology and cytokines in the laboratory of Dr. Robert Gallo.
Ms. Haugen is a 14-year inflammatory breast cancer survivor, and is the National Breast Cancer Coalition (NBCC) Field Coordinator for South Dakota and a graduate of all of the NBCC Project LEAD science training courses. She participated in the NBCC Measuring What Matters Project. She has consumer experience in cancer research peer and programmatic review and currently serves as the Chair of the Department of Defense Breast Cancer Research Program Integration Panel. She has also served as a consumer reviewer for the California Breast Cancer Research Program, and as a member of the National Quality Forum Clinician-Level Cancer Care Steering Committee and the Patient Outcomes Steering Committee. Pat serves as a community representative board member on the Sanford Health Institutional Review Board (IRB) for community cooperative group cancer clinical trials, and is a board member of the National Cancer Institute Adult Central IRB. She recently completed service as the consumer representative to the Advisory Board of the Consumer Operated and Oriented Plan (CO-OP) Program. Ms. Haugen has served on the South Dakota State Advisory Council for the American Cancer Society and is a member of the South Dakota Women’s Cancer Network. She also has experience as a public policy advocate and as a SPORE advocate. She spent over 30 years in the information technology industry and serves as a board member in higher education and long-term care. She has an undergraduate degree in mathematics and a certificate in public health.
Virginia Kwitkowski, R.N., M.S., ANCP-BC
Ms. Kwitkowski joined the U.S. Food and Drug Administration (FDA) as a Senior Clinical Analyst in 2006. She is currently a clinical team leader in the Division of Hematology Products within the Office of Hematology and Oncology Products. In this role, she provides leadership to a team of clinical reviewers who review Investigational New Drug Applications and New Drug Applications for Benign and Malignant Hematology indications. Prior to joining the FDA, Ms. Kwitkowski was a Nurse Practitioner in the Medicine Branch of the National Cancer Institute.
Shakun Malik, M.D.
Dr. Malik joined the Center for Drug Evaluation and Research branch of the Food and Drug Administration (FDA) in the Office of Hematology and Oncology Products in January 2009. In addition to her duties at the FDA, she continues with her clinical activities at the National Cancer Institute in the thoracic oncology clinic. Prior to joining FDA she worked as an Associate Professor of Medicine in the Department of Hematology/Oncology at the Georgetown University Hospital since October 2001. She served as the Chief of Center for Thoracic Oncology and Director of the Multi-Disciplinary Thoracic Oncology Clinic at the Lombardi Cancer Center. She also worked as an Associate in the phase I program of drug and developmental therapeutics. She is a graduate of The University of Kashmir, India. She completed her fellowship at The George Washington University and research with Human Genome project at the National Institutes of Health. Her interest remains in lung cancer and development of new markers and therapeutic options for lung cancer.
Toshio Miyata, M.D.
Dr. Miyata is currently the Deputy Director of the Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau in the Ministry of Health, Labor and Welfare, the government of Japan. In 2010-2011,he was responsible for the promotion of early-phase clinical trials when he was assistant director of the Research and Development Division, Health Policy Bureau. Dr. Miyata served as an assistant professor of cardiac surgery in Osaka University Medical School. He completed his surgical internship at Osaka Koseinenkin Hospital andresidency of thoracic surgery (lung cancer)at Osaka City General Hospital. He is a graduate of Osaka University Medical School. He received a B.A. degree of engineering (biomedical engineering technology and artificial organ) from Waseda University.
Francesco Pignatti, M.D.
Dr. Pignatti graduated as medical doctor at the University of Rome La Sapienza. In 1995 he became research fellow at the European Organization for Research and Treatment of Cancer Data Center, Brussels, Belgium, where he was involved in numerous activities including clinical trial design, conduct, analysis, and reporting. In 1997 he became Medical Advisor for the Gastrointestinal Tract Cancer Cooperative Group, and Brain Tumor Cooperative Group. In 1997 he obtained a Master of Science degree in Biostatistics from the University of Limbourg, Belgium. In 1999 he joined the European Medicines Agency (EMA) in London. The EMA is responsible, among others, for the scientific evaluation of new oncology drug applications for marketing authorization in the European Union. In 2009 he became Head of Oncology, Hematology and Diagnostics in the sector for Safety and Efficacy of Medicines.
Eric Rubin, M.D.
Dr. Rubin's interest in cancer therapeutics began as an oncology fellow and faculty member at the Dana-Farber Cancer Institute, where he studied DNA topoisomerase I as a therapeutic target, and was the first to demonstrate that resistance to topoisomerase I-targeting drugs such as the camptothecins can occur through mutations that affect DNA binding by the enzyme. He was recruited subsequently to lead the Investigational Therapeutics Division at the Cancer Institute of New Jersey, Robert Wood Johnson Medical School. At this institution he was involved in both drug discovery and development activities. In 2008 Dr. Rubin was recruited to Merck Research Laboratories as Vice-President and Therapeutic Area Head, Oncology Clinical Research. In this role he oversees all clinical oncology research activities, and collaborates with Gary Gilliland and other colleagues at Merck in the application of molecular profiling and biomarker technologies to drug development. Dr. Rubin has authored over 100 original, peer-reviewed publications and book chapters related to oncology clinical trials and the biology of topoisomerases. He has served frequently as a member of National Cancer Institute and American Cancer Society study sections, as well as on program committees for the American Association of Cancer Research and the American Society of Clinical Oncology. In addition, he serves on several editorial boards, including The Journal of Clinical Oncology and Investigational New Drugs, and is a deputy editor for Clinical Cancer Research. Dr. Rubin obtained his medical degree from the University of South Florida and completed his residency in internal medicine at Yale-New Haven Hospital.
Ellen Sigal, Ph.D.
Dr. Sigal is Chairperson and Founder of Friends of Cancer Research (“Friends”), a cancer research think tank and advocacy organization based in the Washington, DC metropolitan area. Friends is dedicated to accelerating the nation's progress toward prevention and treatment of cancer by mobilizing public support for cancer research funding and providing education on key public policy issues. Dr. Sigal is Vice Chair of the inaugural board of directors of the ReaganÃƒÂ¢Ã¢â€šÂ¬Ã¯Â¿Â½Udall Foundation, a partnership designed to modernize medical product development, accelerate innovation, and enhance product safety in collaboration with the U.S. Food and Drug Administration. She serveson the National Institutes of Health Foundation Board chairing its PublicÃƒÂ¢Ã¢â€šÂ¬Ã¯Â¿Â½Private Partnerships Committee, the American Association for Cancer Research Foundation Board, and the Research!America Board. Dr. Sigal is a member of the Stand Up To Cancer (SU2C) Advocate Advisory Council, and she is one of two Council members nominated to the SU2C Scientific Advisory Committee. She holds leadership positions with a broad range of cancer advocacy and public policy organizations, and leadership positions with academic health centers including theM.D. Anderson Cancer Center External Advisory Board, the Duke University Cancer Center Board of Overseers, and The Sidney Kimmel Comprehensive Cancer Center Advisory Council.She serves on the CÃƒÂ¢Ã¢â€šÂ¬Ã¯Â¿Â½Change Research Committee and the Entertainment Industry Foundation Oversight Committee for the Biomarker Discovery Project. Dr. Sigal was recently named to the Patient Centered Outcomes Research Institute Board of Governors as a representative of patients and health consumers.During her more than twenty year commitment to cancer research, Dr. Sigal has served in a number of critical public positions. She served on the National Cancer Institute Board of Scientific Advisors from 2003ÃƒÂ¢Ã¢â€šÂ¬Ã¯Â¿Â½2009, and the National Institutes of Health Director’s Council of Public Representatives from 2003ÃƒÂ¢Ã‹â€ Ã¢â‚¬â„¢2006. She was a Presidential Appointee to the National Cancer Advisory Board from 1992ÃƒÂ¢Ã¢â€šÂ¬Ã¯Â¿Â½1998, where she chaired the Budget and Planning Committee that oversees the federal cancer budget. In 1998, Dr. Sigal was named Vice Chair of the Board of The March, a national grassroots advocacy group that brought thousands of volunteers to Washington to liaise with Congress and to set a new advocacy agenda for cancer research and treatment. She is a past member of the American Society of Clinical Oncology Foundation Board. Dr. Sigal has also been instrumental in harnessing the energies of Hollywood on behalf of cancer research, serving as President of The Creative Community Task Force for Cancer Research.
Howard Soule, Ph.D.
Dr. Soule is Executive Vice President and Chief Science Officer of the Prostate Cancer Foundation. In this capacity he coordinates global academic, government and biopharmaceutical sector research activity and is responsible for the implementation of Prostate Cancer Foundation global research strategies. He is also a member of the Department of Defense Prostate Cancer Research Program Integration Panel. In addition, Dr. Soule is a Senior Fellow of the Milken Institute, a non-partisan economic think tank and parent organization to FasterCures. Dr. Soule was a senior R&D executive for nine years at Corvas International, Inc., a public biotechnology company, and developed innovative products for the treatment of life-threatening cardiovascular diseases. Dr. Soule has considerable experience in medical diagnostic and device industries as well. Dr. Soule received a Ph.D. degree from Baylor College of Medicine in Virology and Epidemiology and was a Post Doctoral Fellow in Immunology and Vascular Biology at the Scripps Research Institute.
Sandra Swain, M.D.
Dr. Swain is the Medical Director of the Washington Cancer Institute, of the Washington Hospital Center, in Washington, DC. She is a Professor of Medicine at Georgetown University and an Adjunct Professor of Medicine for Uniformed Services University of the Health Sciences. She was previously the Deputy Branch Chief of the Medicine Branch, Center for Cancer Research, National Cancer Institute, Department of Health and Human Services and was a tenured Principal Investigator. She was also the Chief of the Breast Cancer Section, and prior to that Chief of the Cancer Therapeutics Branch. Dr. Swain received her undergraduate degree from the University of North Carolina at Chapel Hill and her M.D. from the University of Florida in Gainesville. She then went on to complete an internship and residency at Vanderbilt University in Nashville, TN. She next completed a fellowship in medical oncology at the Medicine Branch, National Cancer Institute. Dr. Swain’s current research interests include translational research to identify novel and targeted therapeutics for metastatic and inflammatory breast cancer. Also, she has a strong interest in the development of adjuvant therapy for breast cancer and the effect of chemotherapy on ovarian function in this setting. She is the chair of three international phase III randomized studies focused on adjuvant treatment of breast cancer. She was instrumental in the approval of dexrazoxane for cardioprotection with anthracyclines for breast cancer treatment. She has published over 200 journal and review articles and has been the featured speaker at hundreds of presentations regarding breast cancer and breast health; both domestically and internationally. She has received an NIH Challenge grant to study health disparities in African Americans in clinical trials. She has also received several Susan G. Komen for the Cure grants to study health disparities and recently received the Susan G. Komen for the Cure Community Global Award of Distinction.Dr. Swain was the recipient of the National Cancer Institute’s Mentor of Merit Award for two years as well as the National Institutes of Health Merit Award. She is a member of the American Society of Clinical Oncology (ASCO), where she served on numerous committees including the nominating committee and as chair of that committee. For 2005-2007 she served as the chair of the education committee. She is currently a member of the ASCO Board and the Conquer Cancer Foundation Board. Dr. Swain is the ASCO President Elect for 2011 and will be ASCO President for 2013-2013. She is a member of the board of directors for the Washington Hospital Center and the Washington Hospital Center Foundation. She has been an active member of the National Surgical Adjuvant Breast and Bowel Project for over 20 years and is currently on the board of directors and is the vice-chair of the breast committee. She is also a member of the American Association of Cancer Research.
Jura Viesulas, M.S., Ed.D.
Dr. Viesulas coordinates the Outreach Program in the Office of Hematology and Oncology Products in the Center for Drug Evaluation and Research of the U.S. Food and Drug Administration. In this role she organizes workshops, monitors office publications, and coordinates other outreach activities. Prior to joining the FDA, Dr. Viesulas was Manager of Professional Services at the American Chemical Society where she organized over 20 workshops and published numerous career manuals and guidelines for chemists. During her academic career she was Coordinator of General and Organic Chemistry at Temple University, Philadelphia. She is author and producer of General Chemistry Laboratory Video Demonstrations and several web courses for chemists. She received her M.S. in Biochemistry from Wayne State University and her Doctor of Education from Temple University.